drugset / Trial / NCT07173738

Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide

NCT07173738

Phase 1 Completed 44 enrolled Bial - Portela C S.A.
RandomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is: * To assess the effect of BIA 5 1058 400 mg on furosemide pharmacokinetics (PK). * To assess the effect of furosemide 40 mg on the PK of BIA 5 1058.

Timeline

Start
2018-06-11
Primary completion
2018-09-07
Completion
2018-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified 40 mg Oral
Subject zamicastat Small molecule 400 mg Oral